Naluzotan

Summary

Naluzotan (CHEMBL209821) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including anxiety and temporal lobe epilepsy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 450.6 Da · C23H38N4O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL209821
Name	Naluzotan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11430856
Molecular formula	C23H38N4O3S
Molecular weight	450.6
InChIKey	SPWZXWDPAWDKQE-UHFFFAOYSA-N

SMILES: CC(=O)NC1=CC(=CC=C1)N2CCN(CC2)CCCCNS(=O)(=O)CC3CCCCC3

IUPAC name: N-[3-[4-[4-(cyclohexylmethylsulfonylamino)butyl]piperazin-1-yl]phenyl]acetamide

Also known as: Naluzotan, PRX-00023, NALUZOTAN

Parent form; salt/anhydrous children: CHEMBL2105647

Patent coverage: 51 distinct patent families (128 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Adrenergic receptor alpha-1, 5-hydroxytryptamine receptor 1A, Voltage-gated inwardly rectifying potassium channel KCNH2, 5-hydroxytryptamine receptor 1A, Sigma non-opioid intracellular receptor 1, 5-hydroxytryptamine receptor 7.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 10 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	8.29	Ki	5.1	nM	CHEMBL_ACT_1718536
P19327	7.77	Ki	17	nM	CHEMBL_ACT_1718650
HTR1A	7.7	EC50	20	nM	CHEMBL_ACT_1718660
P19327	7.52	Ki	30.2	nM	CHEMBL_ACT_1924327
HTR1A	7.03	EC50	93.33	nM	CHEMBL_ACT_1924418
SIGMAR1	7	Ki	100	nM	CHEMBL_ACT_1718793
HTR7	6.16	Ki	700	nM	CHEMBL_ACT_1718659
P15823	5.8	Ki	1600	nM	CHEMBL_ACT_1718554
KCNH2	5.42	IC50	3800	nM	CHEMBL_ACT_1718645
KCNH2	5.42	IC50	3800	nM	CHEMBL_ACT_2294923

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
temporal lobe epilepsy	2	MONDO:0005115	EFO:0000773
major depressive disorder	2	MONDO:0002009	MONDO:0002009

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00248183	PHASE3	COMPLETED	A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)
NCT00448292	PHASE2	COMPLETED	A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder
NCT01281956	PHASE2	TERMINATED	PRX-00023 Therapy in Localization-Related Epilepsy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).